Hanmi Science Co., Ltd. (KRX:008930)

Market Cap	2.31T +21.5%
Revenue (ttm)	1.36T +5.7%
Net Income	118.37B +99.2%
EPS	1,747.00 +99.0%
Shares Out	67.71M
PE Ratio	19.55
Forward PE	n/a
Dividend	300.00 (0.87%)
Ex-Dividend Date	Mar 30, 2026

Volume	98,751
Average Volume	114,138
Open	34,100
Previous Close	34,150
Day's Range	32,800 - 34,450
52-Week Range	32,200 - 55,500
Beta	0.62
RSI	31.45
Earnings Date	Apr 30, 2026

About Hanmi Science

Hanmi Science Co., Ltd., through its subsidiaries, manufactures and sells pharmaceutical products in Korea and internationally. It develops drugs in the areas of diabetes and anti-cancer. The company also offers drug substances, general medicines, health functional foods, and nutrition and health products and services. In addition, it operates an online pharmacy; and offers pharmaceutical management automation systems. The company was formerly known as Hanmi Holdings Co., Ltd. and changed its name to Hanmi Science Co., Ltd. in March 2012. Hanmi...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 1973
• Country: South Korea
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 008930

Financial Performance

In 2025, Hanmi Science's revenue was 1.36 trillion, an increase of 5.73% compared to the previous year's 1.28 trillion. Earnings were 118.37 billion, an increase of 99.20%.